NCT03552445View on ClinicalTrials.gov

Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

462

Participants

Timeline

Start Date

November 1, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

February 28, 2018

Conditions
TetanusDiphtheriaPneumococcal Infections
Interventions
BIOLOGICAL

Tetanus-diphtheria (Td) and PCV13

154 concomitant Td-PCV13 recipients: one dose of each vaccine administered on Day 0

BIOLOGICAL

PCV13 alone

154 PCV13 recipients: one vaccine injection administered on Day 0

BIOLOGICAL

Td alone

437 Td recipients: one vaccine injection administered on Day 0

All Listed Sponsors
lead

Korea University Guro Hospital

OTHER

NCT03552445 - Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine | Biotech Hunter | Biotech Hunter